Protara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Stocks Rankings for TARA.

PROTARA THERAPEUTICS, INC. : News, information and stories for PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq

Protara Therapeutics, Inc. Common Stock (TARA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. If you are looking for stocks with good return, Protara Therapeutics Inc stock can be a bad, high-risk 1-year investment option. Protara Therapeutics Inc real time quote is equal to 16.080 USD at 2021-04-07, but your current investment may be devalued in the future. 2021-03-25 · Protara Therapeutics Company Profile.

Trading performance analysis for TARA stock. Protara Therapeutics Inc. [TARA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.91. Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com. About Us; Pipeline; Careers; Investors 2021-04-06 · Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.

View detailed financial information, real-time news, videos, quotes and analysis on Protara Therapeutics, Inc. (NASDAQ:TARA). Explore commentary on Protara Therapeutics, Inc. and hear what the

Click Here to get the full report on Protara On average, analysts give Protara Therapeutics Inc a Strong Buy rating. The average price target is $45.666, which means analysts expect the stock to add by 109.86% over the next twelve months. That average ranking earns Protara Therapeutics Inc an Analyst Rating of 79, which is better than 79% of stocks based on data compiled by InvestorsObserver. Protara Therapeutics Inc stock news.

Company Profile. Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The

21, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. Protara Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock. Email Print 2014 Employee Stock Purchase Plan (Full title of the plans) Jesse Shefferman. President and Chief Executive Officer. Protara Therapeutics, Inc. 345 Park Avenue South, Third Floor.

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases.
Karnov umu

Barron's also provides information on historical stock ratings, target prices, company earnings, market valuation NEW YORK, Sept.

S&P 500 4,128.80. DOW 33,800.60. QQQ 337.11.
Northvolt skellefteå sweden

Steadfast and tenacious in our search for transformative therapies TARA-002 TARA-002 is the Company's lead investigational cell therapy based on the broad

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The View Protara Therapeutics, Inc. TARA investment & stock information. Get the latest Protara Therapeutics, Inc. TARA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Mediaarkivet

20 Mar 2021 KTRA Stock Kintara Therapeutics Could Triple By End of Year! Rare Disease and Orphan FDA Fastrack!Text Me: (949) 415-6256My podcast is

Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.